Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study D. Deplanque, F. Machuron, N. Waucquier, E. Jozefowicz, S. Duhem, S. Somers, O. Colin, A. Duhamel, R. Bordet
Adverse drug reactions (ADRs) from over 14 million prescriptions of (Stresam®) etifoxine were reviewed and analyzed by the French National Agency for the Safety of Medicines and Health Products, between 2000 and 2012. The average incidence of ADRs was 0.0021% (21 per million treatments) and no cases of abuse, misuse or pharmacodependance were reported.
Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice N. Nguyen, E. Fakra, V. Pradel, E. Jouve, C. Alquier, M-E. Le Guern, J. Micallef, and O. Blin